Key result
Acetylsalicylic acid or dipyridamole fails to reduce increased platelet consumption in metastatic cancer.
Why the study?
Does acetylsalicylic acid or dipyridamole reduce platelet consumption in patients with metastatic cancer?
Does acetylsalicylic acid or dipyridamole reduce platelet consumption in patients with metastatic cancer?
Acetylsalicylic acid and dipyridamole do not appear to reduce platelet consumption in patients with metastatic cancer.
No effect of acetylsalicylic acid or dipyridamole on platelet consumption in metastatic cancer; hypothesis-generating and does not support clinical use.
20 patients with metastatic cancer had increased consumption of blood platelets. Acetylsalicylic acid or dipyridamole in doses known to inhibit platelet aggregation did not reduce the platelet consumption.
No takes yet. Share an insight, caveat, or question.
Arne Foss Abrahamsen (1972) studied this question. Acetylsalicylic acid or dipyridamole did not reduce increased platelet consumption in patients with metastatic cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: